Thalidomide Patent Expiration
Thalidomide is Used for treating multiple myeloma and erythema nodosum leprosum. It was first introduced by Bristol-Myers Squibb Co
Thalidomide Patents
Given below is the list of patents protecting Thalidomide, along with the drug name that holds that patent and the company name owning that drug.
| Drug Used in | Drug Patent Number | Drug Patent Title | Drug Patent Expiry | Drug Owner |
|---|---|---|---|---|
| Thalomid | US7230012 | Pharmaceutical compositions and dosage forms of thalidomide |
Dec 09, 2023
(Expired) | Bristol-myers |
| Thalomid | US6315720 | Methods for delivering a drug to a patient while avoiding the occurrence of an adverse side effect known or suspected of being caused by the drug |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6561977 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6755784 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6869399 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US7141018 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US7959566 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US8315886 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US8626531 | Methods for delivering a drug to a patient while restricting access to the drug by patients for whom the drug may be contraindicated |
Oct 23, 2020
(Expired) | Bristol-myers |
| Thalomid | US6045501 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US6561976 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US6908432 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US7874984 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US8204763 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US8589188 | Methods for delivering a drug to a patient while preventing the exposure of a foetus or other contraindicated individual to the drug |
Aug 28, 2018
(Expired) | Bristol-myers |
| Thalomid | US7435745 | Methods and compositions for inhibition of angiogenesis |
Nov 03, 2017
(Expired) | Bristol-myers |
| Thalomid | US5629327 | Methods and compositions for inhibition of angiogenesis |
May 13, 2014
(Expired) | Bristol-myers |
| Thalomid | US6235756 | Methods and compositions for inhibition of angiogenesis by thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
| Thalomid | US7723361 | Methods for inhibiting undesired angiogenesis in patients having tumors with thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
| Thalomid | US8143283 | Methods for treating blood-born tumors with thalidomide |
Mar 01, 2013
(Expired) | Bristol-myers |
A patent's expiry date may change depending upon legal activities going on that patent. Critical activities like abandoning of a patent, term extension of a patent or amendment of its claims can increase or decrease the life of a patent hence affecting its expiry date and in turn affecting the generic launch date of that drug. Tracking these ongoing activities on a patent application helps to keep an eye on the latest developments in the patent process of the drug which can give an idea of how early a drug's generic could be available. The next section provides a list of recent legal activities on Thalidomide's patents.
Latest Legal Activities on Thalidomide's Patents
Given below is the list recent legal activities going on the following patents of Thalidomide.
| Activity | Date | Patent Number |
|---|---|---|
 | ||
| Expire Patent Critical | 17 Jul, 2023 | US7959566 |
| Expire Patent Critical | 27 Feb, 2023 | US7874984 |
| Maintenance Fee Reminder Mailed Critical | 30 Jan, 2023 | US7959566 |
| Maintenance Fee Reminder Mailed Critical | 12 Sep, 2022 | US7874984 |
| Expire Patent Critical | 16 Nov, 2020 | US7435745(Litigated) |
| Maintenance Fee Reminder Mailed Critical | 01 Jun, 2020 | US7435745(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 14 Dec, 2018 | US7959566 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 12 Dec, 2018 | US7230012(Litigated) |
| Payment of Maintenance Fee, 8th Year, Large Entity | 25 Jul, 2018 | US7874984 |
| Payment of Maintenance Fee, 12th Year, Large Entity | 29 May, 2018 | US7141018 |
Thalidomide's Family Patents
Explore Our Curated Drug Screens
Thalidomide Generic API Manufacturers
Only one generic application has been filed for Thalidomide.
Given below is the list of companies who have filed for Thalidomide generic, along with the locations of their manufacturing plants worldwide.
1. NATCO
Natco Pharma Ltd has filed for 1 generic for Thalidomide. Given below are the details of the strengths of this generic introduced by Natco.
| Strength | Dosage Form | Availability | Application Pathway | TE code | Launch Date |
|---|---|---|---|---|---|
| 150MG | capsule | Discontinued | ORAL | N/A | Apr 27, 2023 |
Manufacturing Plant Locations New
Natco's manufacturing plants are situated in 2 countries - United Kingdom, India. Given below are the details of these plant locations as well as the firm names of Natco as present at those locations.
| Country | City | Firm Name | ||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| United Kingdom |
| |||||||||||||
| India |
| |||||||||||||